Cerestat NMDA receptor antagonist: CNSI discontinued its Phase III trial after an interim analysis indicated a lack of efficacy (see Noteworthy, BioCentury Part

Cambridge NeuroScience Inc. (CNSI), Cambridge, Mass.
Product: Cerestat NMDA

Read the full 91 word article

How to gain access

Continue reading with a
two-week free trial.